These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10217362)

  • 1. Demonstration of the presence of lipid peroxide-modified proteins in human atherosclerotic lesions using a novel lipid peroxide-modified anti-peptide antibody.
    Kim JG; Taylor WR; Parthasarathy S
    Atherosclerosis; 1999 Apr; 143(2):335-40. PubMed ID: 10217362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions.
    Sakata N; Imanaga Y; Meng J; Tachikawa Y; Takebayashi S; Nagai R; Horiuchi S; Itabe H; Takano T
    Atherosclerosis; 1998 Nov; 141(1):61-75. PubMed ID: 9863539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a polyclonal antibody against lipid peroxide-modified proteins.
    Kim JG; Sabbagh F; Santanam N; Wilcox JN; Medford RM; Parthasarathy S
    Free Radic Biol Med; 1997; 23(2):251-9. PubMed ID: 9199887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL.
    Ylä-Herttuala S; Palinski W; Butler SW; Picard S; Steinberg D; Witztum JL
    Arterioscler Thromb; 1994 Jan; 14(1):32-40. PubMed ID: 7506053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides.
    Itabe H; Takeshima E; Iwasaki H; Kimura J; Yoshida Y; Imanaka T; Takano T
    J Biol Chem; 1994 May; 269(21):15274-9. PubMed ID: 8195164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins.
    Malle E; Waeg G; Schreiber R; Gröne EF; Sattler W; Gröne HJ
    Eur J Biochem; 2000 Jul; 267(14):4495-503. PubMed ID: 10880973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo.
    Tsimikas S; Palinski W; Halpern SE; Yeung DW; Curtiss LK; Witztum JL
    J Nucl Cardiol; 1999; 6(1 Pt 1):41-53. PubMed ID: 10070840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein.
    Palinski W; Ylä-Herttuala S; Rosenfeld ME; Butler SW; Socher SA; Parthasarathy S; Curtiss LK; Witztum JL
    Arteriosclerosis; 1990; 10(3):325-35. PubMed ID: 1693068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.
    Palinski W; Hörkkö S; Miller E; Steinbrecher UP; Powell HC; Curtiss LK; Witztum JL
    J Clin Invest; 1996 Aug; 98(3):800-14. PubMed ID: 8698873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit.
    Boyd HC; Gown AM; Wolfbauer G; Chait A
    Am J Pathol; 1989 Nov; 135(5):815-25. PubMed ID: 2683796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esterified lipid hydroperoxide-derived modification of protein: formation of a carboxyalkylamide-type lysine adduct in human atherosclerotic lesions.
    Kawai Y; Fujii H; Kato Y; Kodama M; Naito M; Uchida K; Osawa T
    Biochem Biophys Res Commun; 2004 Jan; 313(2):271-6. PubMed ID: 14684156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques.
    Imanaga Y; Sakata N; Takebayashi S; Matsunaga A; Sasaki J; Arakawa K; Nagai R; Horiuchi S; Itabe H; Takano T
    Atherosclerosis; 2000 Jun; 150(2):343-55. PubMed ID: 10856526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of hypochlorite-modified proteins in human atherosclerotic lesions.
    Hazell LJ; Arnold L; Flowers D; Waeg G; Malle E; Stocker R
    J Clin Invest; 1996 Mar; 97(6):1535-44. PubMed ID: 8617887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating autoantibodies recognizing peroxidase-oxidized low density lipoprotein. Evidence for new antigenic epitopes formed in vivo independently from lipid peroxidation.
    Seccia M; Albano E; Maggi E; Bellomo G
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):134-40. PubMed ID: 9012648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions.
    Moguilevsky N; Zouaoui Boudjeltia K; Babar S; Delrée P; Legssyer I; Carpentier Y; Vanhaeverbeek M; Ducobu J
    Biochem Biophys Res Commun; 2004 Oct; 323(4):1223-8. PubMed ID: 15451427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.
    Ylä-Herttuala S; Palinski W; Rosenfeld ME; Parthasarathy S; Carew TE; Butler S; Witztum JL; Steinberg D
    J Clin Invest; 1989 Oct; 84(4):1086-95. PubMed ID: 2794046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization.
    Torzewski M; Shaw PX; Han KR; Shortal B; Lackner KJ; Witztum JL; Palinski W; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2307-12. PubMed ID: 15528482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for the in vivo generation of oxidatively modified epitopes in patients with atherosclerotic endothelium.
    Le NA; Li X; Kyung S; Brown WV
    Metabolism; 2000 Oct; 49(10):1271-7. PubMed ID: 11079815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins.
    Hammer A; Kager G; Dohr G; Rabl H; Ghassempur I; Jürgens G
    Arterioscler Thromb Vasc Biol; 1995 May; 15(5):704-13. PubMed ID: 7749884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.